Inventaire - dina vänner och gemenskaper är ditt bästa bibliotek

Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.

författare

Yoon Jun Kim

Jihyun An

publicerad i: Gut

utgivningsår: 2015-01-16

språk: engelska

huvudämne: multiple drug resistance, tenofovir, chronic hepatitis B, entecavir

Refererar artiklar 42

Datum

Titel

Författare

2014-02-25

Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine

Ju Hyun Shim
2014-04-01

Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study

Shen-Yung Wang
2014-02-01

No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B.

Patrick Marcellin
2014-06-11

No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B.
2013-10-06

Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population

Anne C. Moorman
2013-03-06

Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection

Hiromitsu Kumada, Fumitaka Suzuki, Kenji Ikeda, Masahiro Kobayashi, Yoshiyuki Suzuki, Norio Akuta, Yasuji Arase, Hitomi Sezaki, Satoshi Saito, Yusuke Kawamura, Mariko Kobayashi, Tetsuya Hosaka
2013-09-30

Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis
2013-10-07

Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection

Jeong-Hoon Lee, Jung-Hwan Yoon
2013-12-22

Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B

Petr Husa, Andrzej Horban
2013-10-25

HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability

Jihyun An
2012-01-01

Management of treatment failure in chronic hepatitis B

Fabien Zoulim
2012-03-01

Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance

Jung-Hwan Yoon, Yoon Jun Kim
2012-07

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection
2012-05-17

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

Jia-Horng Kao, Chun-Jen Liu, Rong-Nan Chien, Stephen Locarnini, Seng Gee Lim, Kwang-Hyub Han, Deepak Amarapurkar, Graham Cooksley, Rosmawati Mohamed, Jin-Lin Hou, Laurentius A Lesmana, Jose D Sollano, Dong-Jin Suh, Yun-Fan Liaw, Masao Omata
2012-09-26

Tenofovir monotherapy and tenofovir plus entecavir combination as rescue therapy for entecavir partial responders

Carrie R Wong
2012-06-26

KASL Clinical Practice Guidelines: Management of chronic hepatitis B.
2012-05-27

Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B

David K Wong
2012-12-03

Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely

Jean-Michel Pawlotsky, Christophe Hézode
2012-05-01

Is hepatitis virus resistance to antiviral drugs a threat?

Jean-Michel Pawlotsky
2011-10-17

Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir.

K. Rajender Reddy
2011-10-26

Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study

Pietro Lampertico, Fabien Zoulim, Thomas Berg, Heiner Wedemeyer, Maria Buti
2010-04-04

Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease

Jong Ryul Eun
2010-02-01

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

Fred Poordad, Waldemar Halota, Uchenna H. Iloeje
2009-09

Chronic hepatitis B: update 2009
2009-05-01

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy
2009-05-01

Antiviral resistance and hepatitis B therapy
2008-08-01

Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.

Hubert G.M. Niesters, Annemiek A van der Eijk
2008-05-10

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

Yun-Fan Liaw
2008-12-01

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

Peter Buggisch, Robert Flisiak, Patrick Marcellin, Maria Buti
2007-07-01

Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management

Jean-Michel Pawlotsky, Yun-Fan Liaw
2007-02-01

Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.
2007-09-02

Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients

Pietro Lampertico, Massimo Iavarone

Artikel - wd:Q41538789

Välkommen till Inventaire

din gemenskap och vänners bibliotek

lär mer